全球蛋白質工程市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

蛋白質工程市場預計將從 2025 年的 40.4 億美元成長到 2034 年的 126 億美元，2026 年至 2034 年的複合年成長率為 13.47%。

受生物技術、藥物研發和合成生物學領域的進步所推動，全球蛋白質工程市場正經歷強勁成長。對標靶治療（包括單株抗體和酵素製劑）的需求不斷成長，正在加速市場擴張。製藥和生物製藥公司正大力投資蛋白質修飾技術，以提高其療法的療效、穩定性和特異性。基因組學和蛋白​​質組學領域的研究活動活性化，也為全球市場的持續成長做出了貢獻。

主要促進因素包括癌症、糖尿病和自體免疫疾病等慢性病的日益普遍，這些疾病需要高度特異性的生物療法。 CRISPR、電腦輔助蛋白質設計和定向進化等技術創新正在提高蛋白質工程的效率。此外，政府和私人機構對生命科學研究投入的增加也促進了市場發展。學術機構和生技公司之間合作的不斷深化也增強了創新管道。

展望未來，個人化醫療的發展趨勢和人工智慧驅動的蛋白質建模技術的進步有望推動市場成長。工業酵素、農業和環境生物技術領域的新應用將豐富收入來源。隨著生物製藥繼續主導藥物開發平臺，蛋白質工程技術的重要性將不減。自動化技術和高通量篩檢方法的整合有望進一步加速全球創新和商業性化應用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球蛋白質工程市場：依最終用戶分類

• 市場分析、洞察與預測
• 製藥和生物技術公司
• 學術研究機構
• 受託研究機構

第5章 全球蛋白質工程市場：依產品分類

• 市場分析、洞察與預測
• 裝置
• 消耗品
• 軟體

第6章 全球蛋白質工程市場：依技術類型分類

• 市場分析、洞察與預測
• 理性誘變或特異性誘變
• 非理性或隨機誘變

第7章 全球蛋白質工程市場：依蛋白質類型分類

• 市場分析、洞察與預測
• 單株抗體
• 胰島素
• 促紅血球生成素
• 干擾素
• 其他

第8章 全球蛋白質工程市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Takara Holdings Inc
  • Amgen Inc
  • Promega Corporation
  • New England Biolabs Inc
  • Danaher Corporation
  • Bio-Rad Laboratories Inc
  • Creative Biolabs Limited
  • Thermo Fisher Scientific Inc
  • Jena Bioscience GmbH
  • Agilent Technologies Inc

The Protein Engineering Market size is expected to reach USD 12.60 Billion in 2034 from USD 4.04 Billion (2025) growing at a CAGR of 13.47% during 2026-2034.

The Global Protein Engineering Market is witnessing robust growth driven by advancements in biotechnology, drug discovery, and synthetic biology. The increasing demand for targeted therapeutics, including monoclonal antibodies and enzyme-based drugs, is accelerating market expansion. Pharmaceutical and biopharmaceutical companies are investing heavily in protein modification technologies to improve efficacy, stability, and specificity of treatments. Rising research activities in genomics and proteomics further contribute to sustained market growth worldwide.

Key drivers include the growing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which require highly specific biologic therapies. Technological innovations like CRISPR, computational protein design, and directed evolution are enhancing protein engineering efficiency. Additionally, increased funding from governments and private organizations for life sciences research supports market development. Expanding collaborations between academic institutions and biotech firms also strengthen innovation pipelines.

In the future, the market is expected to benefit from personalized medicine trends and advancements in artificial intelligence-driven protein modeling. Emerging applications in industrial enzymes, agriculture, and environmental biotechnology will diversify revenue streams. As biologics continue to dominate the pharmaceutical pipeline, protein engineering technologies will remain critical. The integration of automation and high-throughput screening methods is likely to further accelerate innovation and commercial adoption globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By End User

• Pharmaceutical And Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations

By Product

• Instruments
• Consumables
• Software

By Technology Type

• Rational or Site Directed Mutagenesis
• Irrational or Random Mutagenesis

By Protein Type

• Monoclonal Antibodies
• Insulin
• Erythropoietin
• Interferon
• Others

COMPANIES PROFILED

• Takara Holdings Inc, Amgen Inc, Promega Corporation, New England Biolabs Inc, Danaher Corporation, BioRad Laboratories Inc, Creative Biolabs Limited, Thermo Fisher Scientific Inc, Jena Bioscience GmbH, Agilent Technologies Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROTEIN ENGINEERING MARKET: BY END USER 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast End User
• 4.2. Pharmaceutical And Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Academic Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROTEIN ENGINEERING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROTEIN ENGINEERING MARKET: BY TECHNOLOGY TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technology Type
• 6.2. Rational or Site Directed Mutagenesis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Irrational or Random Mutagenesis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROTEIN ENGINEERING MARKET: BY PROTEIN TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Protein Type
• 7.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Insulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Erythropoietin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Interferon Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PROTEIN ENGINEERING MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By End User
  • 8.2.2 By Product
  • 8.2.3 By Technology Type
  • 8.2.4 By Protein Type
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By End User
  • 8.3.2 By Product
  • 8.3.3 By Technology Type
  • 8.3.4 By Protein Type
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By End User
  • 8.4.2 By Product
  • 8.4.3 By Technology Type
  • 8.4.4 By Protein Type
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By End User
  • 8.5.2 By Product
  • 8.5.3 By Technology Type
  • 8.5.4 By Protein Type
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By End User
  • 8.6.2 By Product
  • 8.6.3 By Technology Type
  • 8.6.4 By Protein Type
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PROTEIN ENGINEERING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Takara Holdings Inc
  • 10.2.2 Amgen Inc
  • 10.2.3 Promega Corporation
  • 10.2.4 New England Biolabs Inc
  • 10.2.5 Danaher Corporation
  • 10.2.6 Bio-Rad Laboratories Inc
  • 10.2.7 Creative Biolabs Limited
  • 10.2.8 Thermo Fisher Scientific Inc
  • 10.2.9 Jena Bioscience GmbH
  • 10.2.10 Agilent Technologies Inc